The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK’s (LSE: GSK) biologic therapy Nucala (mepolizumab) has demonstrated a consistent reduction in exacerbation rates among ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...